Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Biosimilar Hormones Market Growth Potential: How Will Market Size Shift Through 2030?
The biosimilar hormones market size has seen substantial growth recently. It is anticipated to increase from $6.22 billion in 2025 to $7.68 billion in 2026, at a compound annual growth rate (CAGR) of 23.5%. The expansion witnessed over the past period is due to elements such as the increasing occurrence of diabetes and hormonal disorders, the significant expense of branded hormone medications, a growing elderly demographic, heightened understanding of hormone replacement therapies, and the enlargement of hospital and retail pharmacy networks.
The biosimilar hormones market size is anticipated to experience substantial growth over the next few years. It is predicted to expand to $18.12 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.9%. This projected growth can be ascribed to factors such as the expiry of patents for significant biologic hormones, increasing regulatory encouragement for biosimilars, a rising need for affordable endocrine treatments, the expansion of online pharmacy distribution networks, and increasing investment in biosimilar research and development. Notable trends for the forecast period include the increasing adoption of biosimilar hormones as economical alternatives, a greater demand for insulin and growth hormone biosimilars, enhanced acceptance of biosimilar hormone therapies among medical professionals, the expanded application of biosimilars in chronic and lifestyle diseases, and more efficient regulatory pathways supporting biosimilar approvals.
Get A Free Sample Report With In-Depth Market Insights:
Biosimilar Hormones Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The biosimilar hormones market is anticipated to expand due to increasing healthcare spending. This spending encompasses all funds utilized by individuals, organizations, or governments for the prevention, treatment, and management of various health conditions. Such expenditure is on the rise, primarily driven by progress in medical technology, as novel diagnostic methods, treatments, and advanced therapies frequently incur higher expenses, thus contributing to an increase in overall healthcare costs. The growth in healthcare spending stimulates the adoption of biosimilar hormones by creating a greater need for economical treatments and improving patient accessibility throughout healthcare systems. For example, data released in December 2024 by the Centers for Medicare & Medicaid Services, a US-based agency overseeing the Medicare and Medicaid programs, indicated that in 2023, health care spending in the U.S. grew by 7.5%, reaching $4.9 trillion, which translates to approximately $14,570 per person. Consequently, the expansion of healthcare expenditure is a key factor fueling the development of the biosimilar hormones market.
Biosimilar Hormones Market Segment Performance And Emerging Opportunities
The biosimilar hormones market covered in this report is segmented –
1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types
2) By Application: Research & Biotechnology, Therapeutics, Other Applications
3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics
Subsegments:
1) By Teriparatide Biosimilars: Osteoporosis Treatment, Bone Health Maintenance
2) By Follitropin Alfa Biosimilars: Infertility Treatment, Assisted Reproductive Technology (ART)
3) By Insulin Biosimilars: Type 1 Diabetes Management, Type 2 Diabetes Management
4) By Somatropin Biosimilars: Growth Hormone Deficiency Treatment, Pediatric Growth Disorders
5) By Other Types: Thyroid Hormones, Corticosteroids
Biosimilar Hormones Market Innovation Trends Shaping Future Development
Leading companies in the biosimilar hormones market are introducing new products, such as the Sogroya (somapacitan-beco) injection, to enhance their market profitability. Sogroya (somapacitan-beco) is a prescription analog of human growth hormone (GH) used for treating individuals diagnosed with growth hormone deficiency (GHD). For example, in April 2023, Novo Nordisk, a pharmaceutical firm from Denmark, secured FDA approval for an additional indication for Sogroya (somapacitan-beco) injection, intended for children aged 2.5 years and older experiencing growth failure due to insufficient endogenous growth hormone secretion. Sogroya is unique as the only once-weekly growth hormone (GH) therapy developed for both children and adults. This approval was granted following results from the phase 3 REAL4 trial, which confirmed Sogroya’s effectiveness in managing growth hormone deficiency (GHD) in pediatric patients.
Biosimilar Hormones Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the biosimilar hormones market are Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz Group AG, LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy’s Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Alvotech, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt
View The Full Biosimilar Hormones Market Report:
Biosimilar Hormones Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the biosimilar hormones market in 2025. The regions covered in the biosimilar hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
